Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences

Diabetes and Vascular Disease Research

Volumn 12, Issue 2, 2015, Pages 78-89

  Gallo, Linda A ^a   Wright, Ernest M ^b   Vallon, Volker ^c,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

anti diabetic therapy; cardiovascular outcomes; kidney physiology; Renal glucose reabsorption

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; GLUCOSE TRANSPORTER; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; PHLORIZIN; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOTAGLIFLOZIN; T 1095; TOFOGLIFLOZIN; UNCLASSIFIED DRUG; URIC ACID; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SLC5A1 PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN;

ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; GLUCOTOXICITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE ABSORPTION; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; MALABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; URIC ACID URINE LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; TREATMENT OUTCOME; URINARY EXCRETION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, PROXIMAL; MOLECULAR TARGETED THERAPY; RENAL ELIMINATION; RENAL REABSORPTION; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84923527667     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164114561992     Document Type: Article

References (90)

1. IDF diabetes Atlas. 6 th ed.Brussels: International Diabetes Federation, 2013. Brussels: International Diabetes Federation ; 2013 :
2. Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011 ; 364: 829-841
3. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 ; 360: 129-139
4. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 ; 358: 2560-2572
5. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 ; 358: 2545-2559
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 ; 352: 837-853
7. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 ; 359: 1577-1589
8. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 ; 353: 2643-2653
9. Inzucchi SE.. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002 ; 287: 360-372
10. Bell DS.. Do sulfonylurea drugs increase the risk of cardiac events?. CMAJ. 2006 ; 174: 185-186
11. Chow E, Bernjak A, Williams S, et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014 ; 63: 1738-1747
12. Hasan FM, Alsahli M, Gerich JE.. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014 ; 104: 297-322
13. Meyer C, Woerle HJ, Dostou JM, et al. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am J Physiol Endocrinol Metab. 2004 ; 287: E1049 - E1056
14. Gerich JE.. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010 ; 27: 136-142
15. Barfuss DW, Schafer JA.. Differences in active and passive glucose transport along the proximal nephron. Am J Physiol. 1981 ; 241: F322 - F332
16. Turner RJ, Moran A.. Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies. Am J Physiol. 1982 ; 242: F406 - F414
17. Wright EM, Loo DD, Hirayama BA.. Biology of human sodium glucose transporters. Physiol Rev. 2011 ; 91: 733-794
18. Wright EM, Turk E.. The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004 ; 447: 510-518
19. Peerce BE, Wright EM.. Conformational changes in the intestinal brush border sodium-glucose cotransporter labeled with fluorescein isothiocyanate. Proc Natl Acad Sci U S A. 1984 ; 81: 2223-2226
20. Hediger MA, Coady MJ, Ikeda TS, et al. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature. 1987 ; 330: 379-381
21. Martin MG, Turk E, Lostao MP, et al. Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat Genet. 1996 ; 12: 216-220
22. Wells RG, Pajor AM, Kanai Y, et al. Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol. 1992 ; 263: F459 - F465
23. Faham S, Watanabe A, Besserer GM, et al. The crystal structure of a sodium galactose transporter reveals mechanistic insights into Na+/sugar symport. Science. 2008 ; 321: 810-814
24. Watanabe A, Choe S, Chaptal V, et al. The mechanism of sodium and substrate release from the binding pocket of vSGLT. Nature. 2010 ; 468: 988-991
25. Hummel CS, Lu C, Loo DD, et al. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol. 2011 ; 300: C14 - C21
26. Sala-Rabanal M, Hirayama BA, Loo DD, et al. Bridging the gap between structure and kinetics of human SGLT1. Am J Physiol Cell Physiol. 2012 ; 302: C1293 - C1305
27. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011 ; 22: 104-112
28. Vallon V, Grahammer F, Volkl H, et al. KCNQ1-dependent transport in renal and gastrointestinal epithelia. Proc Natl Acad Sci U S A. 2005 ; 102: 17864-17869
29. Vallon V, Grahammer F, Richter K, et al. Role of KCNE1-dependent K+ fluxes in mouse proximal tubule. J Am Soc Nephrol. 2001 ; 12: 2003-2011
30. Schmidt UM, Eddy B, Fraser CM, et al. Isolation of (a subunit of) the Na+/D-glucose cotransporter(s) of rabbit intestinal brush border membranes using monoclonal antibodies. FEBS Lett. 1983 ; 161: 279-283
31. Takata K, Kasahara T, Kasahara M, et al. Localization of Na(+)-dependent active type and erythrocyte/HepG2-type glucose transporters in rat kidney: immunofluorescence and immunogold study. J Histochem Cytochem. 1991 ; 39: 287-298
32. Cramer SC, Pardridge WM, Hirayama BA, et al. Colocalization of GLUT2 glucose transporter, sodium/glucose cotransporter, and gamma-glutamyl transpeptidase in rat kidney with double-peroxidase immunocytochemistry. Diabetes. 1992 ; 41: 766-770
33. Takata K, Kasahara T, Kasahara M, et al. Immunohistochemical localization of Na(+)-dependent glucose transporter in rat jejunum. Cell Tissue Res. 1992 ; 267: 3-9
34. Hwang ES, Hirayama BA, Wright EM.. Distribution of the SGLT1 Na+/glucose cotransporter and mRNA along the crypt-villus axis of rabbit small intestine. Biochem Biophys Res Commun. 1991 ; 181: 1208-1217
35. Hirayama BA, Wong HC, Smith CD, et al. Intestinal and renal Na+/glucose cotransporters share common structures. Am J Physiol. 1991 ; 261: C296 - C304
36. Hediger MA, Turk E, Wright EM.. Homology of the human intestinal Na+/glucose and Escherichia coli Na+/proline cotransporters. Proc Natl Acad Sci U S A. 1989 ; 86: 5748-5752
37. Turk E, Zabel B, Mundlos S, et al. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature. 1991 ; 350: 354-356
38. Gorboulev V, Schurmann A, Vallon V, et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes. 2012 ; 61: 187-196
39. Santer R, Calado J.. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010 ; 5: 133-141
40. Rieg T, Masuda T, Gerasimova M, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol. 2014 ; 306: F188 - F193
41. Farber SJ, Berger EY, Earle DP.. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest. 1951 ; 30: 125-129
42. DeFronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013 ; 36: 3169-3176
43. Vallon V.. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol. 2011 ; 300: R1009 - R1022
44. Vallon V, Rose M, Gerasimova M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol. 2013 ; 304: F156 - F167
45. Morrisey K, Steadman R, Williams JD, et al. Renal proximal tubular cell fibronectin accumulation in response to glucose is polyol pathway dependent. Kidney Int. 1999 ; 55: 2548-2572
46. Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells - renoprotection in diabetic nephropathy?. PLoS One. 2013 ; 8: e54442
47. Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014 ; 306: F194 - F204
48. Ghezzi C, Wright EM.. Regulation of the human Na+-dependent glucose cotransporter hSGLT2. Am J Physiol Cell Physiol. 2012 ; 303: C348 - C354
49. Tiwari S, Riazi S, Ecelbarger CA.. Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Renal Physiol. 2007 ; 293: F974 - F984
50. Tabatabai NM, Sharma M, Blumenthal SS, et al. Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res Clin Pract. 2009 ; 83: e27 - e30
51. Petersen C.. Analyse des Phloridzins. Annales Académie Science Française. 1835 ; 15: 178
52. von Mering J.. Ueber kuenstlichen diabetes. Centralbl Med Wiss. 1886 ; xxii: 531
53. Chasis H, Jolliffe N, Smith HW.. The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man. J Clin Invest. 1933 ; 12: 1083-1090
54. Chao EC, Henry RR.. SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010 ; 9: 551-559
55. Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987 ; 79: 1510-1515
56. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 ; 375: 2223-2233
57. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009 ; 85: 520-526
58. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014 ; 124: 509-514
59. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013 ; 36: 2154-2161
60. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014 ; 37: 1480-1483
61. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014 ; 129: 587-597
62. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014 ; 13: 28
63. Poole RM, Dungo RT.. Ipragliflozin: first global approval. Drugs. 2014 ; 74: 611-617
64. Markham A, Elkinson S.. Luseogliflozin: first global approval. Drugs. 2014 ; 74: 945-950
65. Nagata T, Fukuzawa T, Takeda M, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol. 2013 ; 170: 519-531
66. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 ; 92: 158-169
67. Leiter LA, Cefalu WT, de Bruin TW, et al. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014 ; 62: 1252-1262
68. Ghezzi C, Hirayama BA, Gorraitz E, et al. SGLT2 inhibitors act from the extracellular surface of the cell membrane. Physiol Rep. 2014 ; 2: e12058
69. Hummel CS, Lu C, Liu J, et al. Structural selectivity of human SGLT inhibitors. Am J Physiol Cell Physiol. 2012 ; 302: C373 - C382
70. Powell DR, DaCosta CM, Gay J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab. 2013 ; 304: E117 - E130
71. Caulfield MJ, Munroe PB, O'Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 2008 ; 5: e197
72. Andrade JA, Kang HC, Greffin S, et al. Serum uric acid and disorders of glucose metabolism: the role of glycosuria. Braz J Med Biol Res. 2014 ; 47: 917-923
73. Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012 ; 44: 375-393
74. Augustin R, Carayannopoulos MO, Dowd LO, et al. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem. 2004 ; 279: 16229-16236
75. Forbes JM, Cooper ME.. Mechanisms of diabetic complications. Physiol Rev. 2013 ; 93: 137-188
76. Ly JP, Onay T, Sison K, et al. The Sweet Pee model for Sglt2 mutation. J Am Soc Nephrol. 2011 ; 22: 113-123
77. Scholl-Burgi S, Santer R, Ehrich JH.. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant. 2004 ; 19: 2394-2396
78. Kojima N, Williams JM, Takahashi T, et al. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther. 2013 ; 345: 464-472
79. Vallon V, Richter K, Blantz RC, et al. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol. 1999 ; 10: 2569-2576
80. Vallon V, Thomson SC.. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol. 2012 ; 74: 351-375
81. Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012 ; 302: R75 - R83
82. Vallon V.. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015 ; 66: 15.1-15.6
83. Standards of medical care in diabetes. Diabetes Care. 2014 ; 37: S14 - S80
84. Guthrie RM.. Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Postgrad Med. 2013 ; 125: 21-32
85. Pessoa TD, Campos LC, Carraro-Lacroix L, et al. Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol. 2014 ; 25: 2028-2039
86. Beloto-Silva O, Machado UF, Oliveira-Souza M.. Glucose-induced regulation of NHEs activity and SGLTs expression involves the PKA signaling pathway. J Membr Biol. 2011 ; 239: 157-165
87. Fu YG, Gerasimova M, Mayoux E, et al. SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration (Abstr.). Diabetes. 2014 ; 63: A132
88. Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011 ; 60: 890-898
89. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012 ; 97: 1020-1031
90. FDA briefing document. NDA 202293, 2011, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingsMaterials/drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm262994.pdf